TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of recurrent, refractory, or progressive low-risk disease: single-system or multisystem LCH
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
The optimal therapy for patients with recurrent, refractory, or progressive LCH has not been determined.
Treatment options for patients with recurrent, refractory, or progressive low-risk, single-system or multisystem LCH include the following:
Chemotherapy.
Source links and citations
Bisphosphonate therapy.
Source links and citations
Continue within this section
Preserved source evidence · Not medical advice